Fundz

Atsena Therapeutics, Inc. reported raising $27.5 Million in an initial SEC Form D filing, from an offering of $55 Million

PRIVATEDec 23, 2020$27.5M of $55M raised

Amount Raised

$27.5 Million

$27.5 Million sold, per SEC Form D (first sale Dec 23, 2020)

Round Type

Venture

DurhamBiotechnology

Quick answer

Atsena Therapeutics raised $27.5 Million in a funding round, dated December 23, 2020. Atsena Therapeutics is based in Durham, North Carolina, United States.

How much did Atsena Therapeutics raise?
Atsena Therapeutics raised $27.5 Million in a funding round on December 23, 2020.
What does Atsena Therapeutics do?
Atsena Therapeutics is a clinical-stage gene therapy company developing best-in-class treatments for the reversal or prevention of blindness from inherited retinal diseases.
Where is Atsena Therapeutics based and how big is it?
Atsena Therapeutics is based in Durham, North Carolina, United States. Fundz records about 38 employees.
Who are the decision-makers at Atsena Therapeutics?
Fundz holds 1 contact at Atsena Therapeutics, including the Executive Officer, Director. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Atsena Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • ISOThrive raised $5.2M on February 5, 2021.
  • Kate Therapeutics raised $16M on February 5, 2021.
  • Anpath Group, Inc. raised $2.5M (Seed) on February 5, 2021.
  • Exacis Biotherapeutics Inc. raised $50K (Seed) on February 4, 2021.
  • NeuraMedica raised $1.1M (Seed) on February 4, 2021.
  • Circle8 Group Inc raised $350K (Seed) on February 3, 2021.

Who to call at Atsena Therapeutics, and when

A new round usually means Atsena Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Atsena Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Atsena Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Atsena Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Atsena Therapeutics

Location

8 Davis Drive Suite 300

Durham, North Carolina, United States

About

Atsena Therapeutics is a clinical-stage gene therapy company developing best-in-class treatments for the reversal or prevention of blindness from inherited retinal diseases. The company’s lead program is evaluating ATSN-201 in an ongoing Phase 1 / 2 / 3 clinical trial for X-linked retinoschisis (XLRS), a genetic condition that is typically diagnosed in childhood and leads to blindness later in life. ATSN-101, Atsena’s first-in-class, investigational gene therapy for Leber congenital amaurosis type 1 (LCA1), has completed a Phase 1 / 2 trial with positive results (https://doi.org/10.1016/s0140-6736(24)01447-8). Atsena is advancing ATSN-101 toward the initiation of a global pivotal trial as part of its exclusive strategic collaboration with Nippon Shinyaku Co., Ltd. Atsena’s pipeline is powered by novel adeno-associated virus (AAV) technology tailored to overcome the hurdles presented by inherited retinal diseases. Founded by pioneers in ocular gene therapy, Atsena is led by an experienced team dedicated to addressing the needs of patients with vision loss.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Atsena Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsPatrick R., Executive Officer, DirectorSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Atsena Therapeutics's next move

See what Strategic adds

Atsena Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.